Photocure ASA NOK0.5
Photocure ASA NOK0.5
1,31 %
54,30 NOK
0,70
Noter.
54,30
Høy
55,00
Endring
1,31 %
Lav
53,40
Oppdatert
14:42:36
Åpen
53,60
Factsheet for Photocure ASA NOK0.5
Company Profile
Description
PhotoCure ASA is a Norway based specialty pharmaceutical company. Its technology platform is focused on the field of photodynamic diagnosis and treatment in the areas of dermatology and cancer. The group has operations in Norway, Sweden, Denmark, Finland and the United States. The operating segments of the group are Commercial franchise and Development portfolio. The company markets product through its commercial operation in the Nordic region under the brand name Hexvix and in the US under the brand name Cysview. It generates prime revenue from the Commercial franchise segment which includes the Hexvix and Cysview products. In addition, the firm also has two device products, Cevira and Visonac, both targeted at indications with medical need and market potential.
Key Stats
Website: https://www.photocure.com
Headquarter country: Norway
Employees: 50
Market Cap (at close 27.08.2019): NOK 1B
Fiscal Year Ends: desember
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 109,70 113,50
Forward Price/Earnings 40,00 58,10 454,50 89,30
Price/Free Cash Flow
Return on Assets -14,90 -12,60 13,20 -14,00 -8,60
Return on Equity -18,60 -14,80 15,30 -16,10 -9,70
Return on Invested Capital -19,20 -15,60 15,50 -16,40 -6,90
Dividend


Dividend/Share:2,00
Ex. Dividend Date:31.12.2013
Trailing Dividend Yield:9,09
Payout Ratio:0,00
Date Currency Amount
30.06.2013 NOK 2,00
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 181,51 150,91 143,63 134,72 128,95
Gross Profit 0,16 0,14 0,13 0,13 0,12
Gross Margin % 90,55% 92,04% 93,50% 93,90% 94,57%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA -10,00 -33,00 -8,00 -18,00 -5,00
Net income -37,00 -35,00 35,00 -36,00 -25,00
Basic Earnings Per Share -1,70 -1,61 1,64 -1,69 -1,16
Operating Income -0,02 -0,05 -0,02 -0,02 -0,01
Operating Margin % -13,06% -29,95% -11,04% -16,32% -4,37%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow -24,00 -24,00 19,00 -21,00 -6,00
Capital Expenditures -2,00 -19,00 -22,00 -15,00 -1,00
Free Cash Flow -26,00 -42,00 -3,00 -36,00 -7,00
Balance Sheet

Assets 31.12.2018 31.12.2017 31.12.2016 31.12.2015 31.12.2014
Current Assets 153,43 175,61 211,78 204,47 194,07 196,97
Long Term Assets 77,77 87,49 74,07 43,59 76,51 104,76
Total Assets 231,20 263,10 285,85 248,06 270,58 301,73
Liabilities 31.12.2018 31.12.2017 31.12.2016 31.12.2015 31.12.2014
Total Current Liabilities 52,45 40,27 30,15 34,04 27,47 30,31
Long Term Liabilities 3,76 3,96
Total Liabilities 33,91 38,00
Equity 31.12.2018 31.12.2017 31.12.2016 31.12.2015 31.12.2014
Retained Earnings 101,80 149,56 186,39 156,25 191,56 223,65
Treasury Stock
Total Stockholder Equity 176,34 218,08 251,94 210,06 240,06 269,12
Net Tangible Assets 153,84 184,77 225,55 198,18 240,02 268,85